Core Viewpoint - Guangkang Biochemical experienced a decline of 2.41% in stock price on October 30, with a trading volume of 42.54 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On October 30, Guangkang Biochemical had a financing buy-in amount of 3.42 million yuan and a financing repayment of 3.43 million yuan, resulting in a net financing buy of -3,800 yuan [1] - As of October 30, the total financing and securities lending balance for Guangkang Biochemical was 75.25 million yuan, accounting for 7.12% of its circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high financing balance [1] - The company had no securities lending transactions on October 30, with a securities lending balance of 0.00 yuan, placing it in the 90th percentile level over the past year, suggesting a high level of securities lending activity [1] Company Overview - Guangkang Biochemical, established on October 17, 2003, and listed on June 27, 2023, is located in Tianhe District, Guangzhou, Guangdong Province [2] - The company specializes in the research, production, and sales of pesticide active ingredients, intermediates, and formulations, and is a major supplier of SDHI, trichloromethylthio fungicides, biphenyl hydrazine acaricides, and pyrethroid insecticides in China [2] - The revenue composition of Guangkang Biochemical includes 82.42% from active ingredients, 17.31% from formulations, 0.15% from pesticide intermediates, and 0.12% from other sources [2] Financial Performance - For the period from January to September 2025, Guangkang Biochemical achieved a revenue of 550 million yuan, representing a year-on-year growth of 13.53% [2] - The net profit attributable to shareholders for the same period was 34.84 million yuan, reflecting a significant year-on-year increase of 47.10% [2] Dividend Information - Since its A-share listing, Guangkang Biochemical has distributed a total of 49.95 million yuan in dividends [3]

Core Viewpoint - The company, Guangdong Guangkang Biochemical Technology Co., Ltd., has released its third-quarter financial report, ensuring the accuracy and completeness of the information disclosed, with no significant omissions or misleading statements [1][2]. Financial Data Summary - The third-quarter financial report has not been audited [6]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable to the company [3]. Shareholder Information - The report includes details on the total number of common shareholders and the top ten shareholders' holdings [4]. - There are no changes in the top ten shareholders due to securities lending activities [5]. Management Assurance - The board of directors, audit committee, and senior management have guaranteed the authenticity and completeness of the quarterly report, accepting legal responsibility for any inaccuracies [2].

Core Insights - Guangkang Biochemical reported a revenue of 549,873,806.69 yuan for the first three quarters of 2025, representing a year-on-year growth of 13.53% [2] - The net profit attributable to shareholders of the listed company was 34,848,362.42 yuan, showing a significant year-on-year increase of 47.10% [2] Financial Performance - Revenue for the first three quarters of 2025 reached approximately 549.87 million yuan, up from the previous year [2] - Net profit for the same period was around 34.85 million yuan, indicating strong growth compared to the prior year [2]

Major Events - Former Chairman of Beiyin Wealth Management, Fang Yi, has joined Huaxia Bank as Chief Risk Officer, pending regulatory approval [4] - Xilai Materials' subsidiary plans to invest 2 billion yuan in a semiconductor core component project, expected to generate over 1.5 billion yuan in annual output after reaching production [5][6] - Huatai Securities' subsidiary Huatai Futures has appointed Zhao Changtao as the new chairman [7] - Chuanfa Longmang's subsidiary plans to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Huagong Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - Jiangsu Leili's actual controller has changed from Su Jianguo to both Su Jianguo and Su Da due to internal share transfers [10] - Electric Power Investment Energy has been unable to contact independent director Han Fang, but this does not affect the board's operation [11] - Qiaqia Food's subsidiary is establishing an investment company focused on the leisure food industry with a total investment of 4 billion yuan [12][13] - Steel Research High-tech plans to set up a wholly-owned subsidiary in Saudi Arabia with an investment of up to 138 million yuan [14] - Yangjie Technology has terminated the acquisition of 100% equity in Better Electronics due to differences in business types and management [15] Performance Reports - Youfa Group reported a 2320.53% increase in net profit for Q3, despite a 3.97% decline in revenue [16] - Zhuoyi Information's net profit increased by 2074.65% in Q3, with revenue growth of 2.52% [17] - North Navigation's Q3 net profit surged by 1681.27%, with a 52.12% increase in revenue [18] - Tianneng Heavy Industry's net profit grew by 1359.03% in Q3, driven by increased sales of tower tubes [19] - Te Yi Pharmaceutical's net profit rose by 985.18% in Q3, with significant growth in traditional Chinese medicine sales [20] - Hualgreen Bio's Q3 net profit increased by 619.37%, with a 35.24% rise in revenue [21] - Zhenlei Technology's net profit grew by 598.09% in Q3, supported by strong revenue growth [22] - Shengyi Electronics expects a net profit increase of 476% to 519% for the first three quarters of 2025 [23] - Glodon reported a 244.89% increase in Q3 net profit, despite a slight decline in revenue [24] - Yingli Co., Ltd. saw a 229.14% increase in Q3 net profit, with a 14.73% rise in revenue [25] - Guangkang Biochemical's Q3 net profit increased by 236.87%, despite a decline in revenue [26] - High-speed Electric's Q3 net profit rose by 242.35%, with a 44.51% increase in revenue [27] - Wide Special Materials reported a 213.65% increase in net profit for Q3, driven by improved gross margins [28] - Baofeng Energy's Q3 net profit increased by 162.34%, attributed to increased production capacity [29] - Sanfu Co., Ltd. reported a 162.25% increase in Q3 net profit, driven by improved profitability of potassium and silane products [30] - Wuku New Energy's Q3 net profit increased by 106.31%, despite a loss in the first three quarters [32] - Pioneering Technology's Q3 net profit grew by 94.01%, supported by a recovery in the household energy storage market [33] - Sanlife Guojian's net profit increased by 71.15% in Q3, driven by project collaboration and CDMO business growth [34] - BGI Genomics reported a loss of 120 million yuan in the first three quarters, despite revenue growth [35] - Rejing Bio reported a net loss of 10.9 million yuan in the first three quarters, impacted by industry policies [36] - Jiangshan Oupai reported a net loss of 51.58 million yuan in Q3, attributed to market downturns and increased competition [38] - Taiping Bird reported a net loss of 49.45 million yuan in Q3, due to declining revenue and increased inventory losses [39] - Zhongke Tongda reported a loss of 6.87 million yuan in the first three quarters, affected by project delays and market competition [40] - Wolong New Energy reported a loss of 579.7 thousand yuan in Q3, transitioning from profit to loss [41] Major Contracts - Jinggong Steel Structure signed a significant overseas project contract worth approximately 1.23 billion yuan [42][43] - New Beiyang's subsidiary won a 105 million yuan postal equipment outsourcing project [44] - Maipu Medical plans to sign product sales agency agreements with related parties, with estimated procurement amounts of 21.5 million yuan and 3.5 million yuan [45] Shareholding Changes - Yunlu Co., Ltd. shareholder Guo Keyun plans to reduce his stake by up to 3% [46] Financing - Xinda Securities has received approval from the CSRC to issue up to 10 billion yuan in technology innovation corporate bonds [47]

Group 1 - HuanGong Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [1] - XinLai YingCai's subsidiary plans to invest 2 billion yuan in a semiconductor core component project, aiming for an annual output value exceeding 1.5 billion yuan [2] - ChuanFa LongMang's subsidiary intends to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project to strengthen its new energy materials business [4] Group 2 - YouFa Group reported a net profit increase of 2320.53% in Q3, with a revenue of 13.104 billion yuan, down 3.97% year-on-year [6] - ZhuoYi Information's Q3 net profit rose by 2074.65%, with revenues of 88.8168 million yuan, up 2.52% year-on-year [5] - BeiFang Navigation's Q3 net profit increased by 1681.27%, with revenues of 765 million yuan, up 52.12% year-on-year [6] Group 3 - TianNeng Heavy Industry reported a Q3 net profit growth of 1359.03%, with revenues of 1.055 billion yuan, up 59.33% year-on-year [7][8] - TeYi Pharmaceutical's Q3 net profit increased by 985.18%, with revenues of 201 million yuan, up 41.49% year-on-year [9] - HuaLv Biological's Q3 net profit grew by 619.37%, with revenues of 369 million yuan, up 35.24% year-on-year [10] Group 4 - ShengYi Electronics expects a net profit increase of 476% to 519% for the first three quarters, with revenues projected between 6.614 billion yuan and 7.034 billion yuan [12] - YingLi Co., Ltd. reported a Q3 net profit increase of 229.14%, with revenues of 581 million yuan, up 14.73% year-on-year [13] - GuangKang Biochemical's Q3 net profit increased by 236.87%, with revenues of 151 million yuan, down 9.41% year-on-year [14] Group 5 - High-speed Electric reported a Q3 net profit growth of 242.35%, with revenues of 277 million yuan, up 44.51% year-on-year [15] - Wide Special Materials reported a Q3 net profit increase of 213.65%, with revenues of 1.24 billion yuan, up 15.03% year-on-year [16] - BaoFeng Energy's Q3 net profit increased by 162.34%, with revenues of 12.725 billion yuan, up 72.49% year-on-year [17] Group 6 - Sanfu Co., Ltd. reported a Q3 net profit increase of 162.25%, with revenues of 540 million yuan, up 23.52% year-on-year [18] - WuKang New Energy's Q3 net profit increased by 106.31%, with revenues of 2.15 billion yuan, up 69.79% year-on-year [19] - PaiNeng Technology's Q3 net profit grew by 94.01%, with revenues of 863 million yuan, up 56.13% year-on-year [20] Group 7 - SanSheng GuoJian reported a Q3 net profit increase of 71.15%, with revenues of 474 million yuan, up 38.27% year-on-year [21] - ReJing Biological reported a net loss of 109 million yuan for the first three quarters, with revenues of 310 million yuan, down 19.8% year-on-year [22] - JiangShan OuPai reported a Q3 net loss of 51.58 million yuan, with revenues of 416 million yuan, down 48.92% year-on-year [23][24]

Core Viewpoint - Guangkang Biochemical (300804.SZ) reported a revenue of 550 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 13.53% [1] - The net profit attributable to shareholders reached 34.8484 million yuan, marking a year-on-year increase of 47.10% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 32.4105 million yuan, showing a significant year-on-year growth of 169.48% [1] - The basic earnings per share stood at 0.4709 yuan [1]

华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为广东广康生化科技股份有限公司（以下简称"广康生化"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐机构，根据《证券发行上市保荐 业务管理办法》《深圳证券交易所创业板股票上市规则》及《深圳证券交易所上 市公司自律监管指引第13号——保荐业务》等有关规定，对广康生化本次全资子 公司与关联方共同投资暨关联交易事项进行审慎核查，具体核查情况如下： 一、关联交易概述 （一）基本情况 核查意见 华泰联合证券有限责任公司 关于广东广康生化科技股份有限公司 全资子公司与关联方共同投资暨关联交易的核查意见 为落实公司战略规划，充分调动公司管理团队的积极性和创造性，激发组织 活力，实现个人发展与公司目标的有机统一，构建风险共担、利益共享的业务平 台，推动公司业务快速健康发展，公司全资子公司广州禾农生物科技有限公司（以 下简称"广州禾农"）拟与自然人王世银先生、吴光辉先生、车林先生共同投资 设立韶关禾农作物科技有限公司（以下简称"韶关禾农"或"合资公司"，最终 名称以市场监督管理部门核准登记为准）。 合资公司注册资本为人民币300.00万元，其中： ...

Core Insights - Guangkang Biotech (300804) reported a 9.41% year-on-year decline in Q3 revenue, totaling 151 million yuan, while net profit attributable to shareholders increased by 236.87% to 5.83 million yuan [1] - For the first three quarters, the company achieved a revenue of 550 million yuan, reflecting a 13.53% year-on-year growth, and a net profit of 34.84 million yuan, up 47.1% year-on-year [1] Financial Performance - Q3 revenue: 151 million yuan, down 9.41% year-on-year [1] - Q3 net profit: 5.83 million yuan, up 236.87% year-on-year [1] - Year-to-date revenue: 550 million yuan, up 13.53% year-on-year [1] - Year-to-date net profit: 34.84 million yuan, up 47.1% year-on-year [1] Strategic Developments - The company announced plans to establish a joint venture, Shaoguan Henong Crop Technology Co., Ltd., with natural persons Wang Shiyin, Wu Guanghui, and Che Lin [1] - The registered capital of the joint venture is 3 million yuan, with Guangkang Biotech's subsidiary, Guangzhou Henong, contributing 2.55 million yuan, representing 85% of the total investment [1]

证券代码：300804 证券简称：广康生化 公告编号：2025-053 广东广康生化科技股份有限公司 关于全资子公司与关联方共同投资暨关联交易的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 （一）基本情况 为落实公司战略规划，充分调动公司管理团队的积极性和创造性，激发组织 活力，实现个人发展与公司目标的有机统一，构建风险共担、利益共享的业务平 台，推动公司业务快速健康发展，公司全资子公司广州禾农生物科技有限公司（以 下简称"广州禾农"）拟与自然人王世银先生、吴光辉先生、车林先生共同投资 设立韶关禾农作物科技有限公司（以下简称"韶关禾农"或"合资公司"，最终 名称以市场监督管理部门核准登记为准）。 合资公司注册资本为人民币300万元，其中：广州禾农以货币方式出资255 万元，占合资公司注册资本的85%；王世银先生、吴光辉先生、车林先生各以货 币方式出资15万元，分别占合资公司注册资本的5%。 （二）关联关系说明 共同投资方车林先生、王世银先生系公司副总经理，吴光辉先生为公司董事。 根据《深圳证券交易所创业板股票上市规则》及《公司章程》 ...

Core Viewpoint - Guangkang Biotech announced the establishment of a joint venture, Shaoguan Henong, with related parties, which involves an investment of 3 million yuan, with no significant adverse impact on the company's finances or operations [1] Group 1: Joint Venture Details - The board of directors approved the investment proposal on October 23, 2025 [1] - The registered capital of the joint venture is 3 million yuan, with Guangzhou Henong contributing 2.55 million yuan, accounting for 85% [1] - Three related individuals, who are the company's deputy general manager and directors, will each contribute 150,000 yuan, representing 5% each [1] Group 2: Transaction Characteristics - The transaction is classified as a related party transaction but does not constitute a major asset restructuring [1] - The pricing follows the principle of fairness, and the funding comes from the company's own resources [1] - The transaction is stated to have no significant adverse impact on the company's financial and operational status [1]